AIOVA™ is KweHealth’s pioneering investigational platform that unites the regenerative power of amniotic fluid–derived mesenchymal stem cells (AF-MSCs) with the bioactive potential of amniotic fluid–derived exosomes. Designed as a combinatory approach, AIOVA™ harnesses both the cellular and extracellular dimensions of regeneration, offering a uniquely powerful strategy for tissue repair and functional recovery.

Each dose of AIOVA™ delivers approximately 50 million AF-MSCs, isolated and expanded under stringent GMP conditions to ensure quality and consistency. These stem cells are characterized by their immunomodulatory, proliferative, and differentiation capabilities, while the accompanying exosomes act as potent biological messengers—carrying growth factors, cytokines, and microRNAs that orchestrate healing responses across damaged tissues.

Potential Applications

• Spinal Cord Injuries — AF-MSCs and their exosomes may support neuronal survival, angiogenesis, and immune modulation, creating a more permissive environment for repair and partial functional recovery.

• Orthopedic & Musculoskeletal Repair — With the capacity to differentiate into bone, cartilage, and muscle, AIOVA™ may aid in the repair of fractures, osteochondral defects, tendon injuries, and degenerative conditions.

• Wound Healing & Tissue Regeneration — Through the release of pro-regenerative factors, AIOVA™ has the potential to accelerate wound closure, enhance vascularization, and improve long-term tissue integrity.

AIOVA™ is being investigated in patients with severe injuries, degenerative disorders, or post-surgical recovery needs where conventional treatments offer limited benefit. Its experimental use highlights the potential to address complex, refractory conditions in regenerative medicine.

As an investigational product, AIOVA™ is not yet approved for therapeutic use. While manufactured under GMP standards, it requires continued rigorous evaluation to determine its safety, efficacy, and best-use protocols. Special precautions are under consideration for immunocompromised patients, those with active infections, pregnancy, or malignancy.

By combining the cellular potency of AF-MSCs with the regenerative signaling of exosomes, AIOVA™ represents a new frontier in regenerative therapeutics. Though still experimental, its dual-action profile positions it as a transformative platform under investigation for some of the most challenging injuries and degenerative conditions—most notably spinal cord injury.

AIOVA™ — Dual-powered by cells and exosomes to unlock the future of regenerative healing.